Readers may find this article interesting: https://www.gastroendonews.com/Priority-Report-Hepatology-Insights/Article/11-23/abnormal-liver-enzyme-patients/72355?sub=4C55C5630E93618BB5BC5103818CA65D911B8A2DAFEEA2D88A31872C32E&tken=4CC4F71BB2E9937C086D224907A3499F71D63C5DCC74012D371F0B7B489EA8&enl=true&dgid=&utm_source=enl&utm_campaign=20240430&utm_content=3&pos=3&utm_medium=button
Some useful info:
The terms “liver function tests,” or “LFTs,” are not exactly correct. Although some liver tests—such as bilirubin, albumin, and international normalized ratio—do relate to liver function, liver tests such as AST, ALT, and alkaline phosphatase relate more to liver injury and/or other structural issues. For this reason, this article uses the terms abnormal liver chemistries, tests, or enzymes and specifically focuses on the evaluation of patients with abnormal ALT, AST, alkaline phosphatase, and/or bilirubin.
In the 2017 clinical guideline on abnormal liver chemistries from American College of Gastroenterology (ACG), based on many studies and surveys of many of the world’s leading hepatologists, we proposed that the true ULN for ALT should be 29 to 33 U/L in males and 19 to 25 U/L in females.